-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Obesity, diabetes , hypertension and heart vascular disease are risk factors for chronic kidney disease (CKD) and kidney failure
Obesity, diabetes , hypertension and heart vascular disease are risk factors for chronic kidney disease (CKD) and kidney failure
The initial stage of the inflammatory response to injury or metabolic dysfunction reflects the release of pro-inflammatory mediators, including polypeptides, lipids and cytokines, as well as the recruitment of leukocytes
The initial stage of the inflammatory response to injury or metabolic dysfunction reflects the release of pro-inflammatory mediators, including polypeptides, lipids and cytokines, as well as the recruitment of leukocytes
Key points:
Key points: Key points: Key points:- The role of inflammation in the pathogenesis of diabetes and obesity-related nephropathy has received more and more attention.
The interaction of adipose tissue with the kidney through the fat-renal axis is important for normal renal function and response to metabolic damage (Figure 1)
Elevated plasma triglycerides, fatty acids, and low-density lipoprotein cholesterol can induce renal dysfunction by promoting lipotoxicity, insulin resistance, and pro-inflammatory pathways called obesity-related glomerular disease (ORG)Figure 1.
Figure 1.
Specialized lipid-promoting mediators (SPMs) are synthesized through the interaction between endothelial cells and/or epithelial cells and infiltrating polymorphonuclear cells (PMN) at the site of tissue injury
The biological effects of promoting decomposition of SPM include inhibiting endothelial cell activation, blocking neutrophil extravasation, promoting non-inflammatory monocyte recruitment, promoting an (M2) decomposition of macrophage phenotype, stimulating neutrophil apoptosis and macrophages Proliferation of phagocytic effector cellsThe role of lipid-promoting mediators in the resolution of inflammation
The role of lipid-promoting mediators in the resolution of inflammationFrom a therapeutic point of view, one of the main limitations of using endogenous SPMs is their relative instability, but this can be avoided by the design of artificial simulants
From a therapeutic point of view, one of the main limitations of using endogenous SPMs is their relative instability, but this can be avoided by the design of artificial simulants
In addition, the extent to which existing treatments can regulate the inflammation of diabetes and obesity is still unclear.
References: Brennan, E.
, Kantharidis, P.
, Cooper, ME et al.
Pro-resolving lipid mediators: regulators of inflammation, metabolism and kidney function.
Nat Rev Nephrol (2021).
https://doi.
org/10.
1038 /s41581-021-00454-y References: Brennan, E.
, Kantharidis, P.
, Cooper, ME et al.
Pro-resolving lipid mediators: regulators of inflammation, metabolism and kidney function.
Nat Rev Nephrol (2021).
https ://doi.
org/10.
1038/s41581-021-00454-y Brennan, E.
, Kantharidis, P.
, Cooper, ME et al.
Pro-resolving lipid mediators: regulators of inflammation, metabolism and kidney function.
Nat Rev Nephrol (2021).
https://doi.
org/10.
1038/s41581-021-00454-y https://doi.
org/10.
1038/s41581-021-00454-y
Leave a message here
